In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Growth

Set Alert for Growth

Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?

The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?

Outlook 2022 Growth

Infographic: Top 100 Pharma Companies

The Scrip 100 universe gathers FY 2020 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales. 

Outlook 2022 Commercial

Novartis Slips Into Pfizer's Number One Pharma Slot Amid Leaderboard Shakeup

Pfizer has dropped to number seven in our top pharma rankings after a long reign. AbbVie has risen to number three, growing through merger expansion.

Outlook 2022 Commercial

Big Cardio Medtechs Are Moving ESG Agenda To Center Stage In 2022

In Vivo outlines major trends shaping the top 15 cardiovascular device companies included in the latest Medtech 100 rankings. They include a growing need to reach underserved patient populations, ongoing staffing and other challenges created by the COVID-19 pandemic, and reimbursement obstacles.

Medical Device Cardiology

SPAC Mergers Are Viable Funding Tools, But The Test Is Yet To Come

Dozens of health care-focused special purpose acquisition corporations have gone public during the past two years but many biopharma firms that have merged with SPACs have not performed well to date, raising the question of how long the SPAC boom will last.

Deals Financing

Point Of Care Diagnostics In 2022: New Technology But Old Problems

Following a busy year for point of care diagnostics, the industry is facing a period of consolidation. The drive for new technologies is being countered by regulatory and financial issues.

Diagnostics Outlook 2022

Managing Lifecycles Amid Stifling Competition

Biopharma is entering a new period of intense competition from new sources, requiring a change in approach to portfolio strategy and lifecycle management.

Business Strategies Research & Development

Make, Buy Or Partner: Strategic Alliances Continue To Fuel Biopharma Growth

The biopharma market has been highly active throughout the COVID-19 pandemic with a substantial focus on strategic alliances between 2020-H1 2021. Partnership deals present exciting liquidity and risk mitigation opportunities for early-stage companies. Small molecules still comprise the largest segment of partnered drugs, but alliances for other modalities are on the rise.

Business Strategies Commercial

Vietnam On The Verge Of Change

Vietnam’s pharma market has seen constant growth over the last decade, driven by rising incomes and an aging population. Spending on drugs is expected to rise by more than 10% in 2021.

Vietnam Coronavirus COVID-19

Biotech Foundations: Networks And Lab Space Are As Crucial As Funding

BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies. 

StartUps and SMEs Financing

Lithuania Caps Off Decade Of Growth With Stellar 2020

Lithuania’s life sciences sector has harnessed the country’s talent, infrastructure and government support to realize a decade of unprecedented growth. With the industry now maturing, can the Baltic state overcome challenges to become a significant European player?

Growth Business Strategies

Effective Drug Promotion After COVID: Follow Your Audience

Pharmaceutical marketing and sales shifted toward digital by necessity as the COVID-19 pandemic set in, but advertising experts say offline channels still have an important place in an effective, multi-channel promotional strategy. Defining a brand’s key audience and customer drivers should be the determining factor in channel selection, not chasing the next new media platform.

Commercial Strategies Market Intelligence
See All
UsernamePublicRestriction

Register